Most women with HR-positive, HER2-negative, axillary node-negative early-stage breast cancer can skip chemotherapy: results from TAILORx. Also today, maintenance chemotherapy represents the first treatment advancement in rhabdomyosarcoma in 30 years, a tumor analysis suggests testing all MSI-high patients for Lynch Syndrome, and black men with metastatic castration-resistant prostate cancer have a stronger response to abiraterone (Zytinga).